Pieter Sonneveld Selected Research

pomalidomide

2/2022	Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry.
2/2022	Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
1/2022	Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
1/2022	Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial.
1/2021	Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse.
1/2021	Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
1/2019	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
10/2018	Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial.
1/2017	Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function.
9/2015	Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pieter Sonneveld Research Topics

Disease

175	Multiple Myeloma 02/2022 - 03/2003
25	Neoplasms (Cancer) 05/2022 - 01/2005
16	Disease Progression 10/2022 - 06/2005
13	Peripheral Nervous System Diseases (PNS Diseases) 01/2018 - 01/2006
10	Thrombocytopenia (Thrombopenia) 02/2022 - 01/2006
10	Neutropenia 02/2022 - 10/2008
8	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2011 - 08/2003
7	Residual Neoplasm 02/2022 - 03/2017
7	Infections 01/2021 - 05/2013
7	Non-Hodgkin Lymphoma (Lymphosarcoma) 06/2008 - 01/2003
5	Pain (Aches) 01/2021 - 04/2008
5	Amyloidosis 10/2020 - 03/2004
4	Pneumonia (Pneumonitis) 02/2022 - 10/2013
4	Chromosome Aberrations (Chromosome Abnormalities) 01/2022 - 01/2012
4	Anemia 11/2018 - 10/2015
4	Waldenstrom Macroglobulinemia (Macroglobulinemia) 01/2017 - 07/2007
4	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 08/2013 - 03/2008
4	Renal Insufficiency (Renal Failure) 06/2013 - 12/2008
3	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 02/2022 - 04/2004
3	Testicular Neoplasms (Testicular Cancer) 01/2022 - 10/2010
3	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 10/2021 - 08/2005
3	Immunoglobulin Light-chain Amyloidosis 10/2020 - 01/2018
3	Fatigue 10/2018 - 10/2013
2	COVID-19 02/2022 - 01/2020
2	Bone Diseases (Bone Disease) 01/2022 - 10/2015
2	Lymphopenia (Lymphocytopenia) 10/2021 - 11/2018
2	Hypertension (High Blood Pressure) 10/2021 - 07/2010
2	Lymphoma (Lymphomas) 01/2021 - 07/2007
2	Inflammation (Inflammations) 01/2021 - 03/2011
2	Painful Neuropathy 01/2018 - 01/2015
2	Neuralgia (Stump Neuralgia) 01/2018 - 01/2015
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2018 - 01/2017
2	Thrombosis (Thrombus) 10/2016 - 07/2010
2	Polyneuropathies (Polyneuropathy) 01/2015 - 01/2010
2	Hematologic Neoplasms (Hematological Malignancy) 01/2015 - 10/2010
2	Thromboembolism 06/2011 - 04/2008
2	B-Cell Lymphoma (Lymphoma, B Cell) 06/2011 - 06/2008
2	Venous Thrombosis (Deep-Vein Thrombosis) 01/2011 - 10/2008
2	Refractory Anemia 04/2010 - 09/2009
2	Pulmonary Embolism 12/2008 - 10/2008
2	Venous Thromboembolism 12/2008 - 07/2008
2	Breast Neoplasms (Breast Cancer) 05/2007 - 12/2002

Drug/Important Bio-Agent (IBA)

80	Bortezomib (Velcade)FDA Link 01/2022 - 06/2005
62	Dexamethasone (Maxidex)FDA LinkGeneric 02/2022 - 03/2003
41	Lenalidomide (CC 5013)FDA Link 02/2022 - 04/2008
34	Thalidomide (Thalomid)FDA Link 10/2021 - 01/2008
19	Proteasome InhibitorsIBA 02/2022 - 01/2006
19	Pharmaceutical PreparationsIBA 01/2022 - 07/2004
18	daratumumabIBA 10/2022 - 01/2016
17	Melphalan (Alkeran)FDA LinkGeneric 10/2020 - 03/2003
12	pomalidomideIBA 02/2022 - 10/2013
12	Monoclonal AntibodiesIBA 01/2022 - 06/2008
11	Proteins (Proteins, Gene)FDA Link 11/2020 - 12/2002
11	Prednisone (Sone)FDA LinkGeneric 06/2020 - 01/2003
9	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 01/2003
8	Immunomodulating AgentsIBA 01/2022 - 01/2010
8	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021 - 01/2003
7	carfilzomibIBA 01/2021 - 07/2014
7	Vincristine (Oncovin)FDA LinkGeneric 05/2015 - 01/2003
7	Cytarabine (Cytosar-U)FDA LinkGeneric 08/2013 - 04/2004
6	melflufenIBA 02/2022 - 04/2020
6	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2017 - 06/2007
6	liposomal doxorubicin (Doxil)FDA Link 07/2016 - 09/2007
5	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2021 - 05/2005
5	1-dodecylpyridoxal (PLD)IBA 07/2016 - 09/2007
5	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 02/2012 - 08/2003
4	Biological ProductsIBA 11/2020 - 06/2014
4	AnthracyclinesIBA 01/2018 - 07/2004
4	DNA (Deoxyribonucleic Acid)IBA 04/2017 - 04/2007
4	Imatinib Mesylate (Gleevec)FDA Link 08/2013 - 03/2008
4	EnzymesIBA 11/2010 - 10/2006
4	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 11/2010 - 12/2002
3	AntigensIBA 01/2022 - 10/2010
3	Chimeric Antigen ReceptorsIBA 02/2021 - 12/2019
3	Alkylating AgentsIBA 09/2020 - 02/2012
3	Daunorubicin (Cerubidine)FDA LinkGeneric 09/2009 - 07/2004
3	thiamine triphosphorate (TTP)IBA 04/2008 - 03/2003
3	major vault proteinIBA 05/2007 - 12/2002
3	Green Fluorescent ProteinsIBA 02/2006 - 11/2003
2	ATP-Binding Cassette Transporters (ABC Transporters)IBA 01/2022 - 12/2002
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2018
2	ixazomibIBA 01/2021 - 12/2020
2	CytokinesIBA 01/2021 - 04/2016
2	Complement System Proteins (Complement)IBA 12/2020 - 06/2008
2	AminopeptidasesIBA 09/2020 - 10/2010
2	Peptides (Polypeptides)IBA 09/2020 - 04/2020
2	Immunoglobulin G (IgG)IBA 11/2018 - 06/2014
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2018 - 05/2013
2	Rituximab (Mabthera)FDA Link 01/2017 - 11/2013
2	CreatinineIBA 01/2016 - 12/2008
2	Amyloid (Amyloid Fibrils)IBA 05/2015 - 03/2004
2	Factor VIII (Coagulation Factor VIII)IBA 07/2010 - 07/2007
2	valspodar (PSC 833)IBA 02/2006 - 10/2005

Therapy/Procedure

79	Therapeutics 10/2022 - 03/2003
24	Stem Cell Transplantation 01/2021 - 05/2003
17	Drug Therapy (Chemotherapy) 06/2020 - 01/2003
5	Transplantation 01/2021 - 09/2005
3	Induction Chemotherapy 04/2010 - 08/2003
2	Remission Induction 08/2020 - 03/2003
2	Drug Tapering 02/2012 - 04/2008